Vir Biotechnology (VIR) Operating Leases (2020 - 2026)

Vir Biotechnology has disclosed Operating Leases across 7 years of filings, most recently posting $86.6 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $86.6 million, down 1.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (down 1.74% YoY), and the FY2025 annual result was $89.1 million, down 9.03% from the prior year.
• Operating Leases came in at $86.6 million for Q1 2026 at Vir Biotechnology, down from $89.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $132.8 million in Q1 2022 to a low of $86.6 million in Q1 2026.
• The 5-year median for Operating Leases is $109.2 million (2024), against an average of $107.5 million.
• Across the five-year window, Operating Leases surged 99.37% in 2022 and decreased 19.35% in 2024, its largest moves.
• Vir Biotechnology's Operating Leases stood at $128.0 million in 2022, then slipped by 12.74% to $111.7 million in 2023, then dropped by 12.34% to $97.9 million in 2024, then dropped by 9.03% to $89.1 million in 2025, then decreased by 2.72% to $86.6 million in 2026.
• The last three Operating Leases figures came in at $86.6 million (Q1 2026), $89.1 million (Q4 2025), and $91.2 million (Q3 2025), per Business Quant data.